Glycoprotein IIb/IIIa Receptor Inhibition with Abciximab during Percutaneous Coronary Interventions Increases the Risk of Bleeding in Patients with Impaired Renal Function

By  

Cardiology, Vol. 111, Iss. 4, 2008-04 ,pp. : 247-253

Karger

Access to resources Recommend Favorite

A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes

By  

CARDIOVASCULAR THERAPEUTICS (ELECTRONIC), Vol. 34, Iss. 5, 2016-10 ,pp. : 330-336

John Wiley & Sons Inc

Access to resources Recommend Favorite

Influence of Some Cardiovascular Risk Factors on the Expression of Platelet Glycoprotein IIb/IIIa Receptors in Patients with Myocardial Infarction Treated with Antiplatelet Drugs under Primary Percutaneous Coronary Intervention

By Konopka Anna  

Molecular Diagnosis & Therapy, Vol. 13, Iss. 6, 2009-12 ,pp. : 375-382

Adis International

Access to resources Recommend Favorite

Comparison of heparin and bivalirudin in patients undergoing percutaneous coronary intervention without use of glycoprotein IIb/IIIa inhibitors

By  

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 86, Iss. 3, 2015-09 ,pp. : 390-396

John Wiley & Sons Inc

Access to resources Recommend Favorite

Current Knowledge of the Platelet Glycoprotein IIb/IIIa Receptor Antagonists for the Treatment of Coronary Artery Disease

By  

Pathophysiology of Haemostasis and Thrombosis, Vol. 30, Iss. 3, 2004-11 ,pp. : 27-43

Karger

Access to resources Recommend Favorite